APRINOIA Therapeutics

About

APRINOIA Therapeutics is a clinical-stage biotechnology company based in Cambridge, Massachusetts. Founded in 2015, the company is dedicated to enhancing the diagnosis and treatment of neurodegenerative diseases. Its name reflects a mission to illuminate better approaches in this field. The company develops innovative diagnostic tools aimed at improving early detection and monitoring of neurodegenerative diseases. APRINOIA has a strong therapeutic pipeline that includes small and large molecules targeting protein aggregates linked to conditions such as Alzheimer's and Parkinson's diseases. Notable products include tau degraders that utilize PROTAC technology to address pathological tau aggregates and α-synuclein degraders aimed at treating synucleinopathies. APRINOIA Therapeutics collaborates with leading research institutions to advance its clinical studies and therapeutic assets. The company is positioned to make significant contributions to precision medicine in neuroscience.